Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Income
2 top ASX shares to buy for growing dividends in 2019
⏸️ ASX Shares
3 blue chip ASX shares to buy this week
Share Market News
ASX 200 opens higher on Friday: IOOF share price plunges 30% lower
Index investing
The behaviour gap: Why many investors don't beat the share market
⏸️ Investing
Why Aveo Group (ASX:AOG) was among the big winners on the ASX on Friday
Growth Shares
Here are 3 ASX shares to buy today with $5,000
Growth Shares
Are these the best healthcare shares to buy on the ASX?
⏸️ Investing
5 ASX shares to build a portfolio around
Share Gainers
Why these 4 ASX shares are racing higher today
Share Gainers
Cochlear Limited (ASX: COH) share price jumps on broker upgrade
Share Market News
Experts think the Australian dollar has bottomed and is poised for more gains
52-Week Lows
The Cochlear Limited (ASX:COH) share price just hit a 52-week low: Is it a bargain buy?
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
